Evidence map›Paper›PMID 24733828›Full record

ArticleThe Journal of experimental medicine2014

Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system.

Jessica L Williams, Jigisha R Patel, Brian P Daniels, Robyn S Klein

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jessica L WilliamsDepartment of Internal Medicine, 2 Department of Pathology and Immunology, and 3 Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110.
Jigisha R Patel
Brian P Daniels
Robyn S Klein
General Department of Preventive Medicine · VNWashington University in St. Louis · US

Funding

Validating diffusion MRI biomarkers of inflammation and axon pathologies in EAEP01NS059560 · NINDS · WASHINGTON UNIVERSITY · PI SONG, SHENG-KWEI · 2008 to 2018
$11.3M
NINDS NIH HHS P01 NS059560
6 · The paper itself

Abstract

Current treatment modalities for the neurodegenerative disease multiple sclerosis (MS) use disease-modifying immunosuppressive compounds but do not promote repair. Although several potential targets that may induce myelin production have been identified, there has yet to be an approved therapy that promotes remyelination in the damaged central nervous system (CNS). Remyelination of damaged axons requires the generation of new oligodendrocytes from oligodendrocyte progenitor cells (OPCs). Although OPCs are detected in MS lesions, repair of myelin is limited, contributing to progressive clinical deterioration. In the CNS, the chemokine CXCL12 promotes remyelination via CXCR4 activation on OPCs, resulting in their differentiation into myelinating oligodendrocytes. Although the CXCL12 scavenging receptor CXCR7/ACKR3 (CXCR7) is also expressed by OPCs, its role in myelin repair in the adult CNS is unknown. We show that during cuprizone-induced demyelination, in vivo CXCR7 antagonism augmented OPC proliferation, leading to increased numbers of mature oligodendrocytes within demyelinated lesions. CXCR7-mediated effects on remyelination required CXCR4 activation, as assessed via both phospho-S339-CXCR4-specific antibodies and administration of CXCR4 antagonists. These findings identify a role for CXCR7 in OPC maturation during remyelination and are the first to use a small molecule to therapeutically enhance myelin repair in the demyelinated adult CNS.

Indexed as

Analysis of VarianceAnimalsAxonsBenzylaminesBlotting, WesternBromodeoxyuridineCentral Nervous SystemCyclamsHeterocyclic CompoundsImmunohistochemistryMaleMiceMice, Inbred C57BLMultiple SclerosisMyelin SheathOligodendrogliaBenzylaminesBromodeoxyuridineCmkor1 protein, mouseCXCR4 protein, mouseCyclamsHeterocyclic CompoundsplerixaforReceptors, CXCRReceptors, CXCR4

Identifiers

PMID24733828
PMCPMC4010893
OpenAlexW2125935825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.